Aktuellt
SENASTE
We believe Q4 will be another quarter of strong growth considering the recent announcement that OssDsign has reached the milestone of 500 patients treated with Catalyst. We forecast Catalyst sales of SEK 8m in Q4/22, an increase of about SEK 1.5m q/q. As we head into 2023, we move closer to seeing clinical data on Catalyst, which we believe is the most important datapoint in 2023. We reiterate our mid-point of SEK 11 per share.
LÄS MER
